Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001679082-22-000102
Filing Date
2022-07-27
Accepted
2022-07-27 16:18:20
Documents
62
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q myov-20220630.htm   iXBRL 10-Q 1450468
2 EX-10.1 a06302022myovantex101lette.htm EX-10.1 31112
3 EX-31.1 a06302022myovantex311.htm EX-31.1 10716
4 EX-31.2 a06302022myovantex312.htm EX-31.2 10891
5 EX-32.1 a06302022myovantex321.htm EX-32.1 6490
6 EX-32.2 a06302022myovantex322.htm EX-32.2 6278
  Complete submission text file 0001679082-22-000102.txt   5938951

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT myov-20220630.xsd EX-101.SCH 51599
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT myov-20220630_cal.xml EX-101.CAL 52222
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT myov-20220630_def.xml EX-101.DEF 208028
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT myov-20220630_lab.xml EX-101.LAB 522458
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT myov-20220630_pre.xml EX-101.PRE 331815
56 EXTRACTED XBRL INSTANCE DOCUMENT myov-20220630_htm.xml XML 820763
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44 207-400-3351
Myovant Sciences Ltd. (Filer) CIK: 0001679082 (see all company filings)

EIN.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37929 | Film No.: 221111237
SIC: 2834 Pharmaceutical Preparations